Is AstraZeneca (AZN) Stock Cheap?
AstraZeneca (NYSE:AZN) reports third-quarter results next week, and it has already stuck to one promise this year.
Astrazeneca Plc (AZN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Gotham Asset Management Joel Greenblatt | 0 | $0 | 0% | |
| 2. | NWI Management Hari Hariharan | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $160.57 | 20 | $3,248.81 | 19,288 | 2026-08-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $185.78 | 11,893 | $2,209,481.54 | 19,262 | 2026-05-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 102,629 | $16,571,505 | 2.12% | |
| 2. | 48,578 | $7,843,891 | 1.17% | |
| 3. | 23,076 | $3,726,123 | 0.41% | |
| 4. | 403 | $65,072 | 0.02% | |
| 5. | 72 | $11,354 | 0.01% |
News See All
AbbVie vs. AstraZeneca: Which Pharma Giant Has the Stronger Earnings Growth Story?
AbbVie Inc. (NYSE:ABBV) and AstraZeneca PLC (NYSE:AZN) are both delivering earnings growth, but their latest results reveal different strengths.
AstraZeneca (AZN) Adds Oncology Catalysts. Is the Pipeline Worth Its Earnings Multiple?
Several Oncology Catalysts, One Earnings Question AstraZeneca PLC (NYSE:AZN) enters the October 23-27 European Society for Medical Oncology congress with multiple late-stage oncology updates, including...
11 Best Cancer Stocks to Invest In Now
Cancer’s Burden Keeps the Search for Better Treatments Urgent For cancer patients, progress means more time, fewer side effects, and a better chance of recovery.
10 No-Brainer Stocks to Buy Now
Fed Chair Kevin Warsh gave no hint of another rate hike at an IMF event in Bangkok on October 16, and the odds of an October increase fell to roughly 15% on CME FedWatch, according to Benzinga on October...
AstraZeneca’s Shares Have Fallen, but Is 14.6x Forward Earnings a Buying Opportunity?
AstraZeneca PLC (NYSE:AZN) is lagging the broader market this year so far, with shares declining by over 8%.
AstraZeneca (AZN) Seeks FDA Approval for New Lung Cancer Treatment. Can It Fuel Oncology Growth?
AstraZeneca PLC (US) (NYSE:AZN) is on the cusp of unlocking a new growth engine in lung cancer treatment.
AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
AI startup BioinvestGPT predicted the failure of Novartis AG’s ($NVS) experimental muscular dystrophy drug months before a disappointing Phase 3 re...
Becton Dickinson (BDX) Joins Trump Tariff Exemption Scramble with $19B Investment Plan
U.S. medical device company Becton Dickinson ($BDX) has agreed to invest $19 billion in the U.S. over several years, the company announced in a sta...
AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up
AstraZeneca PLC (NASDAQ:AZN) said on September 28 that it will make a $2 billion equity investment in Summit Therapeutics, Inc. (NASDAQ:SMMT) and run joint trials of the two companies' cancer drugs.
Hedge Fund Resource Center